Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17704938 | 0.91 | DGAT1 (0.32) | DGAT1 | |
| SCHEMBL22264439 | 0.88 | YTHDC1 (0.35) | DGAT1 | |
| SCHEMBL2562784 | 0.88 | CYP1A2 (0.33) | DGAT1 | |
| SCHEMBL22247376 | 0.87 | PGK1 (0.35) | DGAT1 | |
| SCHEMBL22264381 | 0.86 | CNR1 (0.36) | — | |
| SCHEMBL20555542 | 0.86 | DGAT1 (0.32) | DGAT1 | |
| SCHEMBL22247330 | 0.85 | CDK2 (0.32) | — | |
| SCHEMBL22418948 | 0.85 | — | — | |
| SCHEMBL22418947 | 0.85 | — | — | |
| SCHEMBL15456177 | 0.84 | DGAT1 (0.32) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025049641-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| WO-2024233605-A1 | COMPOUNDS AND THEIR USE AGAINST CANCER | TANGO THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20230183243-A1 | HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | VORONOIBIO INC. (KR) | 2023-06-15 | — | — | US | disclosed |
| US-20230183243-A1 | HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | VORONOIBIO INC. (KR) | 2023-06-15 | — | — | US | disclosed |
| US-20230183243-A1 | HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | VORONOIBIO INC. (KR) | 2023-06-15 | — | — | US | disclosed |
| US-20230066011-A1 | PYRROLOPYRIMIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE COMPRISING SAME AS ACTIVE INGREDIENT | VORONOIBIO CO., LTD. (KR) | 2023-03-02 | — | — | US | disclosed |
| US-20230066011-A1 | PYRROLOPYRIMIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE COMPRISING SAME AS ACTIVE INGREDIENT | VORONOIBIO CO., LTD. (KR) | 2023-03-02 | — | — | US | disclosed |
| US-20220119371-A1 | COMPOUND, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-04-21 | — | — | US | disclosed |
| US-11214565-B2 | Compound, compositions, and methods | DENALI THERAPEUTICS INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-11208412-B2 | Pyrrolo-pyrimidine derivative compound, preparation method therefor, and pharmaceutical composition comprising same compound as effective ingredient for preventing or treating protein kinase-related disease | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2021-12-28 | — | — | US | disclosed |
| US-9040547-B2 | Pyrrolopyrimidine and purine derivatives | PFIZER INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040547-B2 | Pyrrolopyrimidine and purine derivatives | PFIZER INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040547-B2 | Pyrrolopyrimidine and purine derivatives | PFIZER INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20130079324-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER INC. | 2013-03-28 | — | — | US | disclosed |
| US-20130079324-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER INC. | 2013-03-28 | — | — | US | disclosed |
| WO-2013042006-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER INC. (US) | 2013-03-28 | — | — | WO | disclosed |
| US-20130079324-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | PFIZER INC. | 2013-03-28 | — | — | US | disclosed |
| EP-2007767-B1 | PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS | VERNALIS R&D LTD (GB) | 2011-11-02 | — | — | EP | disclosed |
| US-20090163490-A1 | Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors | VERNALIS (R&D) LTD. (GB) | 2009-06-25 | — | — | US | disclosed |
| US-20090163490-A1 | Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors | VERNALIS (R&D) LTD. (GB) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11208412-B2 | Pyrrolo-pyrimidine derivative compound, preparation method therefor, and pharmaceutical composition comprising same compound as effective ingredient for preventing or treating protein kinase-related disease | LRRK2, WEE1, WEE2 | DGAT1 1028/4885HSP90AA1 1090/4885 |
| US-20220119371-A1 | COMPOUND, COMPOSITIONS, AND METHODS | LRRK2, PARK7, SNCA | DGAT1 3116/4885HSP90AA1 2976/4885 |
| US-20230183243-A1 | HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | TTK, TTBK1, TTBK2 | DGAT1 1837/4885HSP90AA1 1932/4885 |
| US-11214565-B2 | Compound, compositions, and methods | LRRK2, PARK7, MAPT | DGAT1 3150/4885HSP90AA1 2889/4885 |
| US-20130079324-A1 | PYRROLOPYRIMIDINE AND PURINE DERIVATIVES | TYMP, DPYD, TYMS | DGAT1 4657/4885HSP90AA1 4370/4885 |
| US-20230066011-A1 | PYRROLOPYRIMIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE COMPRISING SAME AS ACTIVE INGREDIENT | LRRK2, BRCA1, PARK7 | DGAT1 3663/4885HSP90AA1 1396/4885 |
| US-20090163490-A1 | Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors | HSP90AA1, HSP90AB1, RAF1 | DGAT1 4262/4885HSP90AA1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.